$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000142545019000083 Filed on August 13, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$20.74M	$18.20M	$15.08M
YoY Change	31.13%	20.71%	27.75%
Cost Of Revenue	$4.849M	$4.581M	$3.807M
YoY Change	26.18%	20.33%	23.2%
Gross Profit	$15.90M	$13.62M	$11.27M
YoY Change	32.71%	20.84%	29.36%
Gross Profit Margin	76.62%	74.83%	74.75%
Selling, General & Admin	$16.04M	$14.18M	$12.28M
YoY Change	33.35%	15.48%	40.75%
% of Gross Profit	100.9%	104.08%	108.92%
Research & Development	$1.396M	$1.234M	$1.115M
YoY Change	24.42%	10.67%	66.92%
% of Gross Profit	8.78%	9.06%	9.89%
Depreciation & Amortization	$1.350M	$1.080M	$720.0K
YoY Change	73.08%	50.0%	22.03%
% of Gross Profit	8.49%	7.93%	6.39%
Operating Expenses	$17.43M	$15.41M	$13.39M
YoY Change	32.59%	15.08%	42.61%
Operating Profit	-$1.539M	-$1.790M	-$2.120M
YoY Change	31.31%	-15.57%	213.15%
Interest Expense	-$1.300M	-$630.0K	-$560.0K
YoY Change	113.11%	12.5%	-13.85%
% of Operating Profit
Other Income/Expense, Net	-$1.338M	-$669.0K	-$572.0K
YoY Change	93.07%	16.96%	-197.11%
Pretax Income	-$2.877M	-$2.459M	-$2.690M
YoY Change	53.85%	-8.59%	111.81%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.664M	-$2.618M	-$2.692M
YoY Change	42.84%	-2.75%	112.64%
Net Earnings / Revenue	-12.84%	-14.38%	-17.86%
Basic Earnings Per Share
Diluted Earnings Per Share	-$181.7K	-$181.3K	-$214.3K
COMMON SHARES
Basic Shares Outstanding	14.94M shares	14.68M shares	12.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.70M	$21.90M	$26.50M
YoY Change	-19.59%	-17.36%	1052.17%
Cash & Equivalents	$19.67M	$21.86M	$26.51M
Short-Term Investments
Other Short-Term Assets	$39.80M	$36.70M	$1.100M
YoY Change	3880.0%	3236.36%	10.0%
Inventory	$34.53M	$32.86M	$25.40M
Prepaid Expenses
Receivables	$14.18M	$14.97M	$9.755M
Other Receivables	$500.0K	$500.0K	$0.00
Total Short-Term Assets	$108.7M	$106.8M	$62.74M
YoY Change	75.8%	70.31%	117.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.53M	$20.92M	$12.77M
YoY Change	68.56%	63.78%	55.73%
Goodwill	$10.73M	$10.97M
YoY Change
Intangibles			$2.340M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$23.17M	$23.67M	$15.11M
YoY Change	54.13%	56.68%	34.91%
TOTAL ASSETS
Total Short-Term Assets	$108.7M	$106.8M	$62.74M
Total Long-Term Assets	$23.17M	$23.67M	$15.11M
Total Assets	$153.4M	$151.4M	$77.85M
YoY Change	99.57%	94.53%	94.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.746M	$6.000M	$5.455M
YoY Change	31.22%	9.99%	-10.57%
Accrued Expenses	$3.900M	$4.000M	$3.200M
YoY Change	18.18%	25.0%	33.33%
Deferred Revenue
YoY Change
Short-Term Debt	$30.00M	$30.00M	$0.00
YoY Change
Long-Term Debt Due	$30.12M	$30.12M	$115.0K
YoY Change	25646.15%	26092.17%	15.0%
Total Short-Term Liabilities	$46.18M	$42.19M	$10.49M
YoY Change	323.09%	302.16%	0.87%
LONG-TERM LIABILITIES
Long-Term Debt	$21.09M	$21.11M	$25.30M
YoY Change	-16.56%	-16.55%	-0.4%
Other Long-Term Liabilities	$45.00K	$100.0K
YoY Change
Total Long-Term Liabilities	$21.14M	$21.16M	$25.30M
YoY Change	-16.39%	-16.35%	-0.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$46.18M	$42.19M	$10.49M
Total Long-Term Liabilities	$21.14M	$21.16M	$25.30M
Total Liabilities	$67.32M	$63.35M	$35.79M
YoY Change	86.0%	77.01%	-0.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$123.4M	-$120.7M	-$110.8M
YoY Change	9.56%	9.0%
Common Stock	$4.000K	$4.000K	$2.000K
YoY Change	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$86.11M	$88.08M	$42.06M
YoY Change
Total Liabilities & Shareholders Equity	$153.4M	$151.4M	$77.85M
YoY Change	99.57%	94.53%	94.61%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$2.664M	-$2.618M	-$2.692M
YoY Change	42.84%	-2.75%	112.64%
Depreciation, Depletion And Amortization	$1.350M	$1.080M	$720.0K
YoY Change	73.08%	50.0%	22.03%
Cash From Operating Activities	-$430.0K	-$6.940M	-$6.640M
YoY Change	-63.87%	4.52%	57.35%
INVESTING ACTIVITIES
Capital Expenditures	-$2.030M	-$3.700M	-$1.420M
YoY Change	75.0%	160.56%	-5.96%
Acquisitions
YoY Change
Other Investing Activities	$280.0K	-$49.97M
YoY Change
Cash From Investing Activities	-$1.730M	-$53.68M	-$1.420M
YoY Change	49.14%	3680.28%	-5.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	450.0K	30.06M	-30.00K
YoY Change	50.0%	-100300.0%	-100.54%
NET CHANGE
Cash From Operating Activities	-430.0K	-6.940M	-6.640M
Cash From Investing Activities	-1.730M	-53.68M	-1.420M
Cash From Financing Activities	450.0K	30.06M	-30.00K
Net Change In Cash	-1.710M	-30.56M	-8.090M
YoY Change	-16.59%	277.75%	3945.0%
FREE CASH FLOW
Cash From Operating Activities	-$430.0K	-$6.940M	-$6.640M
Capital Expenditures	-$2.030M	-$3.700M	-$1.420M
Free Cash Flow	$1.600M	-$3.240M	-$5.220M
YoY Change	-5433.33%	-37.93%	92.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	218000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134000	USD
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
	dei	Entity Shell Company EntityShellCompany	false
	dei	Document Transition Report DocumentTransitionReport	false
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14939462	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14939462	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14538202	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14538202	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14538202	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14538202	shares
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	kids	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
	kids	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	dei	Document Type DocumentType	10-Q
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Entity File Number EntityFileNumber	001-38242
	dei	Entity Registrant Name EntityRegistrantName	OrthoPediatrics Corp
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
	dei	City Area Code CityAreaCode	574
	dei	Local Phone Number LocalPhoneNumber	268-6379
	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
	dei	Trading Symbol TradingSymbol	KIDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Document Transition Report DocumentTransitionReport	false
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14939596	shares
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21858000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	60691000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60691000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	218000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14974000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8999000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	32855000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	25708000	USD
CY2019Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	515000	USD
CY2018Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	502000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1277000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1256000	USD
CY2019Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	35364000	USD
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	106843000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	97156000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20915000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12768000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10458000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1921000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	10971000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	0	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	75000	USD
CY2019Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2170000	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	260000	USD
CY2019Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	23674000	USD
CY2018Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2181000	USD
CY2019Q2	us-gaap	Assets Assets	151432000	USD
CY2018Q4	us-gaap	Assets Assets	112105000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6000000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3971000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4011000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3552000	USD
CY2019Q2	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	121000	USD
CY2018Q4	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	118000	USD
CY2019Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30000000	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24000	USD
CY2019Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	494000	USD
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2019Q2	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21112000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1537000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1576000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	42187000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9217000	USD
CY2018Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21156000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51000	USD
CY2019Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21163000	USD
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21156000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	63350000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	30373000	USD
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14939462	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14939462	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14538202	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14538202	shares
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	209262000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	197442000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120729000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115091000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-455000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-623000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	88082000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151432000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112105000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18200000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15077000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32856000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27171000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4581000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3807000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8582000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6982000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	13619000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	11270000	USD
	us-gaap	Gross Profit GrossProfit	24274000	USD
	us-gaap	Gross Profit GrossProfit	20189000	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7606000	USD
CY2018Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6776000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14153000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12855000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6569000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5499000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12181000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11516000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1234000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1115000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2447000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2333000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	15409000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	13390000	USD
	us-gaap	Operating Expenses OperatingExpenses	28781000	USD
	us-gaap	Operating Expenses OperatingExpenses	26704000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1790000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2120000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4507000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6515000	USD
CY2019Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-632000	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-562000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-935000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1114000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-669000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-572000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-972000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1177000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2459000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2692000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5479000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7692000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7692000	USD
CY2019Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-159000	USD
CY2018Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-159000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2618000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2692000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2692000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5638000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7692000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7692000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2618000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2692000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2692000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5638000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7692000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7692000	USD
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14451979	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12549226	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14409752	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12312814	shares
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2618000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-2692000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5638000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7692000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-133000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-459000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	168000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-377000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-133000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-459000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	168000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-377000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2751000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3151000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5470000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8069000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	301000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	565000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	471000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	80049000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2618000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-133000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10000000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	692000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	88082000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	47495000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	82000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2177000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	44754000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-2692000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-459000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	454000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	42057000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5638000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7692000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1912000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1400000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1163000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2631000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	5499000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	4152000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	232000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-40000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1934000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	357000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1061000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-139000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	377000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-10785000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-11673000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	371000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10414000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11673000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	49926000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	170000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	180000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8514000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4167000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-58610000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4347000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-47000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58657000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4347000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	59000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	56000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	30000000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	657000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30598000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-56000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38473000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16076000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	60691000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60691000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	42582000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26506000	USD
	us-gaap	Interest Paid Net InterestPaidNet	935000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	22218000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	26506000	USD
CY2019Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	360000	USD
CY2018Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21858000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1114000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	267000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	594000	USD
	us-gaap	Stock Issued1 StockIssued1	10000000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:4.22pt;font-weight:400;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:4.22pt;font-weight:400;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard and Pediatric Nailing Platform \| Femur, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. In September 2018, we further expanded operations in Canada selling direct to local hospitals, and in January 2019 we expanded to Belgium and the Netherlands. Additionally, in March 2019 we established a holding company and an operating company in the Netherlands that are expected to enhance our operations in Europe. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On June 4, 2019, we purchased all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. ("Vilex") and all the issued and outstanding units of membership interests in Orthex, LLC ("Orthex") for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as Orthex Hexapod technology which is used to treat pediatrics congenital deformities and limb length discrepancies. Because the current products of Vilex also include adult offerings that are not core to the Company's pediatrics business, the Company has begun taking steps to divest the non-core Vilex assets. The Company anticipates completing the divestiture by the end of 2019. </span></div>Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120729000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115091000	USD
	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1234000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1115000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2447000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2333000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q2	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	40.76
CY2019Q2	kids	Business Combination Escrow Deposit Maximum Term BusinessCombinationEscrowDepositMaximumTerm	P20M
CY2019Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	589000	USD
CY2019Q2	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	414000	USD
CY2019Q2	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	507000	USD
CY2019Q2	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	66000	USD
CY2019Q2	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-159000	USD
CY2019Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-159000	USD
CY2019Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	30000000	USD
CY2018Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2019Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	51233000	USD
CY2018Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	21274000	USD
CY2019Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	30121000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-935000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1114000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	118000	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21112000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21156000	USD
	us-gaap	Royalty Expense RoyaltyExpense	74000	USD
	us-gaap	Royalty Expense RoyaltyExpense	72000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	87345000	USD
CY2018Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	335000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation	16200000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	1062000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	2302000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	9736000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	22430000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	112094	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.32
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y9M18D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21409	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	30.69
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	90685	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.23
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M24D
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6790	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	27.81
	kids	Class Of Warrant Or Right Forfeited Or Expired ClassOfWarrantOrRightForfeitedOrExpired	1811	shares
	kids	Class Of Warrant Or Right Forfeited Or Expired Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightForfeitedOrExpiredWeightedAverageExercisePriceOfWarrantsOrRights	0
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4979	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	27.88
CY2019Q2	kids	Classof Warrantor Right Exercised ClassofWarrantorRightExercised	0	shares
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2618000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2692000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5638000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7692000	USD
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14451979	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12549226	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14409752	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12312814	shares
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	403011	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	347059	shares
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q2	us-gaap	Revenues Revenues	18200000	USD
CY2018Q2	us-gaap	Revenues Revenues	15077000	USD
	us-gaap	Revenues Revenues	32856000	USD
	us-gaap	Revenues Revenues	27171000	USD
CY2019Q2	us-gaap	Revenues Revenues	18200000	USD
CY2018Q2	us-gaap	Revenues Revenues	15077000	USD
	us-gaap	Revenues Revenues	32856000	USD
	us-gaap	Revenues Revenues	27171000	USD
CY2018Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2019Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	75000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	75000	USD
	kids	Researchand Development Arrangement Contractto Performfor Others Minimum Annual Royalty Payment ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment	500000	USD

Files In Submission

Name	View Source	Status
0001425450-19-000083-index-headers.html	Edgar Link	pending
0001425450-19-000083-index.html	Edgar Link	pending
0001425450-19-000083.txt	Edgar Link	pending
0001425450-19-000083-xbrl.zip	Edgar Link	pending
exhibit311-ceocertific.htm	Edgar Link	pending
exhibit312-cfocertific.htm	Edgar Link	pending
exhibit321-ceocertific.htm	Edgar Link	pending
exhibit322-cfocertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20190630.htm	Edgar Link	pending
kids-20190630.xsd	Edgar Link	pending
kids-20190630_cal.xml	Edgar Link	unprocessable
kids-20190630_def.xml	Edgar Link	unprocessable
kids-20190630_htm.xml	Edgar Link	completed
kids-20190630_lab.xml	Edgar Link	unprocessable
kids-20190630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2019 Q3 Form 10-Q Financial Statement

#000142545019000083 Filed on August 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2019 Q3 Form 10-Q Financial Statement

#000142545019000083 Filed on August 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids